Frontier and Thermo Fisher Sign Strategic Manufacturing Partnership to Accelerate the Commercialization of a Novel Broad-spectrum HIV Neutralizing Antibody

  • 2019-09-29  16:26:53


Sep. 26th, 2019

Frontier Biotechnologies (“Frontier Biotech”), a biopharmaceutical company headquartered in China, focusing on innovative drug development for anti-HIV treatment and pain management, and Thermo Fisher Scientific, the world leader in serving science, announced that they have entered into strategic partnership for 3BNC117, a novel broad-spectrum HIV Neutralizing antibody.

“It is a pleasure to work with Thermo Fisher. With the “service gene”, our companies’ collaboration will be a success. And hopefully we can start with drug substance and then collaborate in other areas. I believe there're a lot of synergies between two companies. I hope to bring a win-win to both companies and we are in good hands”, said Changjin Wang, chief executive officer of Frontier Biotechnologies Inc.

Per the agreement, Thermo Fisher’s Pharma Services business will be the exclusive drug substance manufacturing partner of 3BNC117 for Frontier to support the pivotal study, PPQ and global commercial supply. The product will be manufactured at Thermo Fisher’s St. Louis, Missouri, site in the United States. Frontier combines 3BNC117 and Albuvirtide (ABT), a long-acting HIV fusion inhibitor developed by Frontier and has been approved in China in 2018, to create a new mechanism of action, total injection, long-acting, and combination of the two drugs to study its potential to inhibit HIV replication and to clear viral reservoirs in patients through immunotherapy. The new drug combination is currently undergoing clinical phase II trials in China and United States.

“It is really a privilege to serve Frontier. We think of Frontier and also the patients Frontier represents. We’re inspired by the good work Frontier has done that many patients can be benefit from. We would like to contribute more and be part of this. I really feel privileged that you think of us, we’ll do a very good job. The mission of Thermo Fisher is to enable our customer’s success”, said Michel Lagarde, executive vice president and president of Thermo Fisher’s Pharma Services business.

This collaboration will integrate the expertise and regulatory track record of Thermo Fisher in biologics drug development and manufacturing as well as the outstanding innovation capabilities of Frontier in HIV treatment to expedite the commercialization of 3BNC117, to improve treatment for patients with HIV. 


About 3BNC117

3BNC117 is one of the most clinically advanced anti-HIV bNAbs in the world, which not only exhibits long-acting anti-HIV efficacy, but also has been clinically proven to elicit human immune response to curtail HIV-infected cells, resulting in delayed viral rebound (or preventing viral remission). 3BNC117 has also exhibited an excellent safety profile in both healthy and HIV-1-infected individuals. 3BNC117 specifically binds to the CD4 binding site (CD4bs) within HIV-1 envelope glycoprotein 120 (gp120), and its mechanism of action is complementary and potentially synergetic to that of Albuvirtide (ABT),  therefore the combination regimen consisted of Albuvirtide (ABT) and 3BNC117 may lead to a significant paradigm shift of the HIV treatment and provides great potential in achieving maximal HIV viral suppression including multiple drug resistance viruses, as well as to be used for HIV prophylaxis application.

About Frontier

Founded in 2013, Frontier Biotechnologies Inc. (“Frontier Biotech”) is a commercial-stage biopharmaceutical company headquartered in China with global vision and world-class competitiveness. Frontier Biotech is committed to discovering, development, manufacturing, and commercialization of innovative medicines that improve patient health.  Our medicines typically address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. Frontier Biotech's first commercial product was approved by the National Medical Product Administration (NMPA), in May 2018 through a priority review process and has gained accelerated approval.  Two additional drug candidates are currently undergoing multiple clinical trials in Phase I and Phase II in both China and the United States. For more information please visit the company website:

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Thermo Fisher operates the largest contract development manufacturing organization (CDMO), offering drug substance, drug development, clinical trials, drug product and viral vector development and manufacturing solutions to companies of all sizes. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit

About Thermo Fisher Scientific China

Thermo Fisher Scientific (China) Co., Ltd has been operating in China for over 35 years. Headquartered in Shanghai, Thermo Fisher Scientific China has branch offices in Beijing, Guangzhou, Hong Kong, Chengdu, Shenyang, Xian, Nanjing, Wuhan, Kunming and other cities with around 5,000 employees. Our products mainly include analytical instruments, laboratory equipment, chemical reagents, consumables, software and more; providing comprehensive laboratory solutions and serving customers across various industries. In order to meet the local needs in China, we have established 7 manufacturing sites in Shanghai, Beijing, Suzhou and Guangzhou respectively. We also have 8 application centers and demo labs across the country which bring world-class technology and products with application development and training services to local customers. Lastly, we have the China Innovation Center in Shanghai which develops products according to local demands with global advanced technology. We have a nationwide maintenance network and China service training team, including over 2,600 professionals directly providing services for customers. We are committed to enabling our customers to make the world healthier, cleaner and safer. For more information, please visit

Develop Innovative Therapies to Better Human Lives